/JANX

JANX Stock - Janux Therapeutics, Inc.

Q: What is the analyst price target for JANX?

Analyst price target information is not currently available for JANX.

Q: What is JANX's market cap?

Market capitalization information is not currently available for JANX.

Healthcare|Biotechnology|NASDAQ

$13.79-1.71%

$0.24 (-1.71%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+206.4%upside

Target: $42.25

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for JANX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.88

52W High$47.58

52W Low$13.26

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$10.59M	$8.08M	$8.61M	$3.64M	N/A
Gross Profit	$8.53M	$6.13M	$7.77M	$3.64M	$-13,000
Gross Margin	80.5%	75.8%	90.2%	100.0%	N/A
Operating Income	$-98,847,000	$-72,979,000	$-67,091,000	$-32,929,000	$-4,843,000
Net Income	$-68,994,000	$-58,293,000	$-63,059,000	$-32,672,000	$-6,784,000
Net Margin	-651.6%	-721.2%	-732.2%	-898.3%	N/A
EPS	$-1.28	$-1.32	$-1.52	$-0.79	$-0.16

Company Overview

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Visit Website

Earnings History & Surprises

JANX

Beat Rate

67%

Last 18 quarters

Avg Surprise

-10.6%

EPS vs Estimate

Beats / Misses

12/6

Last 12 quarters

Latest EPS

$-0.39

Q4 2025

EPS Surprise History

Q1 24

+32.4%

$-0.25vs$-0.37

Q2 24

+14.3%

$-0.30vs$-0.35

Q3 24

+65.6%

$-0.11vs$-0.32

Q4 24

-37.8%

$-0.51vs$-0.37

Q1 25

+26.5%

$-0.36vs$-0.49

Q2 25

+11.6%

$-0.38vs$-0.43

Q3 25

-14.6%

$-0.55vs$-0.48

Q4 25

+35.0%

$-0.39vs$-0.60

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Feb 26, 2026	$-0.65	—	—	—
Q4 2025	Nov 6, 2025	$-0.60	$-0.39	+35.0%	✓ BEAT
Q3 2025	Aug 7, 2025	$-0.48	$-0.55	-14.6%	✗ MISS
Q2 2025	May 8, 2025	$-0.43	$-0.38	+11.6%	✓ BEAT
Q1 2025	Feb 27, 2025	$-0.49	$-0.36	+26.5%	✓ BEAT
Q4 2024	Nov 6, 2024	$-0.37	$-0.51	-37.8%	✗ MISS
Q3 2024	Aug 7, 2024	$-0.32	$-0.11	+65.6%	✓ BEAT
Q2 2024	May 7, 2024	$-0.35	$-0.30	+14.3%	✓ BEAT
Q1 2024	Mar 8, 2024	$-0.37	$-0.25	+32.4%	✓ BEAT
Q4 2023	Nov 7, 2023	$-0.46	$-0.25	+45.7%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.52	$-0.42	+19.2%	✓ BEAT
Q2 2023	May 9, 2023	$-0.49	$-0.42	+14.3%	✓ BEAT
Q1 2023	Mar 10, 2023	$-0.45	$-0.39	+13.3%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.51	$-0.40	+21.6%	✓ BEAT
Q3 2022	Aug 9, 2022	$-0.37	$-0.41	-10.8%	✗ MISS
Q2 2022	May 10, 2022	$-0.37	$-0.32	+13.5%	✓ BEAT
Q1 2022	Mar 18, 2022	$-0.30	$-0.33	-10.0%	✗ MISS
Q4 2021	Nov 9, 2021	$-0.17	$-0.26	-52.9%	✗ MISS
Q3 2021	Aug 10, 2021	$-0.13	$-0.62	-376.9%	✗ MISS

Frequently Asked Questions about JANX

What is JANX's current stock price?

Janux Therapeutics, Inc. (JANX) is currently trading at $13.79 per share. The stock has moved -1.71% today.

What is the analyst price target for JANX?

The average analyst price target for JANX is $42.25, based on 1 analyst.

What sector is Janux Therapeutics, Inc. in?

Janux Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is JANX's market cap?

Janux Therapeutics, Inc. has a market capitalization of $0.83 billion, making it a small-cap company.

Does JANX pay dividends?

No, Janux Therapeutics, Inc. does not currently pay a dividend to shareholders.